Integrated

Transcend Therapeutics, Inc., established in 1992 in Waltham, Massachusetts, is a clinical-stage company focused on developing pharmaceuticals to address diseases associated with oxidative stress and tissue damage. The company also specializes in creating psychoactive medicines aimed at treating neuropsychiatric disorders. By targeting specific areas of the brain involved in the pathophysiology of these conditions, Transcend Therapeutics aims to enable healthcare providers to facilitate positive changes in brain function and behavior for their patients.

BrainSpace collaborates with physicians, families, financial backers, and other parties with the purpose of eliminating the long-term handicap brought on by brain injury.

Homecoming is a provider of patient engagement tools specifically designed for psychedelic therapy. The company has developed a digital companion application that supports patients throughout their therapeutic process. This application promotes accountability and fosters long-term change by offering personalized guides, tasks, and daily check-ins. Additionally, it provides preparation and integration support within a single, user-friendly platform that includes relevant patient program content. This enables healthcare professionals to effectively guide their patients on their healing journeys, enhancing the therapeutic experience and outcomes.

WellSet Inc., founded in 2018 and headquartered in Los Angeles, California, operates an online platform designed to connect customers with wellness practitioners. The company facilitates the discovery, booking, and recommendation of various wellness providers, including acupuncturists, chiropractors, massage therapists, nutritionists, and health coaches. Additionally, WellSet offers a digital mental health studio that streams live classes daily and provides an extensive on-demand library of holistic practices such as stretching, self-hypnosis, functional medicine, breathwork, EFT tapping, guided journaling, meditation, and more. This comprehensive approach aims to support customers in finding practitioners tailored to their specific wellness needs.

Beckley Psytech Limited is a biotechnology company based in Oxford, United Kingdom, that develops psychedelic drugs aimed at treating psychiatric and neurological disorders. Founded in 2014, it focuses on harnessing the therapeutic potential of substances such as psilocybin to address significant mental health challenges, including depression and other debilitating neuropsychiatric conditions with considerable unmet needs. The company aims to integrate clinically validated psychedelic medicines into mainstream medical practices, offering patients innovative treatment options that differentiate from existing therapies. Through its drug pipeline, Beckley Psytech is committed to providing alternative solutions for those suffering from various mental health issues.

MycoMedica Life Sciences, founded by prominent mycologist Paul Stamets, is a life sciences company focused on developing therapeutic drugs derived from fungi to enhance human health. The company specializes in exploring the healing potential of the fungal genome, particularly in relation to psychiatric and neurological disorders. One of its key innovations, the Stamets Stack, combines unique ingredients not typically found together in nature to maximize the effectiveness of psilocybin for prevention and treatment. By studying various fungal species and their applications, MycoMedica aims to advance fungi-based drug development, ultimately benefiting both individuals and the planet.

Small Pharma Ltd. is a pharmaceutical company based in London, United Kingdom, founded in 2015. The company specializes in developing a rapid-acting antidepressant aimed at treating patients with depression. Small Pharma employs a scalable model of outsourced drug development, leveraging expert intellectual property design to facilitate the transition from academic discovery to commercial products. By assembling specialized teams with proven expertise across essential development disciplines, Small Pharma aims to effectively execute its drug development programs.

Beckley Psytech Limited is a biotechnology company based in Oxford, United Kingdom, that develops psychedelic drugs aimed at treating psychiatric and neurological disorders. Founded in 2014, it focuses on harnessing the therapeutic potential of substances such as psilocybin to address significant mental health challenges, including depression and other debilitating neuropsychiatric conditions with considerable unmet needs. The company aims to integrate clinically validated psychedelic medicines into mainstream medical practices, offering patients innovative treatment options that differentiate from existing therapies. Through its drug pipeline, Beckley Psytech is committed to providing alternative solutions for those suffering from various mental health issues.